Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expenses down 14% to $16.1M. The company initiated its Early Access Program with Baylor College of Medicine and appointed a VP of Global Sales, but reiterated no material revenue in 2026 and expects operating expenses to increase 15-20% YoY. Cash burn continues with $143.4M in cash and investments, sufficient through 2027.
Price Chart
Executive Summary
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expenses down 14% to $16.1M. The company initiated its Early Access Program with Baylor College of Medicine and appointed a VP of Global Sales, but reiterated no material revenue in 2026 and expects operating expenses to increase 15-20% YoY. Cash burn continues with $143.4M in cash and investments, sufficient through 2027.
Key Facts
- Net loss of $14.7M in Q1 2026 vs $16.6M in Q1 2025 (improvement of $1.9M)
- Operating expenses of $16.1M, down 14% from $18.8M a year ago
- Cash, cash equivalents, and investments of $143.4M as of March 31, 2026
- First customer (Baylor College of Medicine) in Early Access Program for Tau proteoform assay
- Appointed Amber Faust as VP of Global Sales from Olink Proteomics and SomaLogic
- No material revenue expected in 2026 from Early Access Program
- Operating expenses expected to increase 15-20% YoY in 2026
- Cash runway sufficient through 2027
- Investment backlog of $1.8B as of April 23, 2026
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001808805-26-000015 |
| Document: naut-20260428.htm | 0001808805-26-000015 |
| Document: 0001808805-26-000015-index-headers.html | 0001808805-26-000015 |
| Document: 0001808805-26-000015-index.html | 0001808805-26-000015 |
| Document: 0001808805-26-000015.txt | 0001808805-26-000015 |
| 8-K Data (Synthetic) | 0001808805-26-000015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 28, 2026 22w ago | Press Release | $2.59 $1.77 | ▼ −31.66% | ▼ −35.65% | $1.86 (−28.38%) |
Apr 28, 2026 22w ago | 8-K | $2.59 $1.77 | ▼ −31.66% | ▼ −35.65% | $1.86 (−28.38%) |
Mar 18, 2026 28w ago | Press Release | $2.74 $2.29 | ▼ −16.61% | ▼ −28.13% | $1.86 (−32.30%) |
Feb 26, 2026 31w ago | 8-K | $2.42 $2.54 | ▲ +4.96% | ▼ −2.79% | $1.86 (−23.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access